AI Article Synopsis
- - Bimekizumab is a monoclonal antibody that targets interleukin-17A and IL-17F, showing promise in treating Psoriatic arthritis (PsA).
- - A systematic review of 4 randomized controlled trials (RCTs) with 892 PsA patients found that bimekizumab significantly improved skin and joint symptoms compared to placebos, although there was a slight increase in overall adverse events.
- - The study concluded that bimekizumab offers meaningful clinical benefits for PsA management while maintaining an acceptable safety profile.
Article Abstract
Background: Bimekizumab, a humanized monoclonal IgG1 antibody targeting both interleukin (IL)-17A and IL-17F, could be effective for treating Psoriatic arthritis (PsA). This study aimed to systematically evaluate the efficacy and safety of bimekizumab in the management of PsA.
Research Design And Methods: A comprehensive literature search by August 2023 was performed through PubMed, Embase, Cochrane Controlled Register of Trials, and ClinicalTrials.gov. investigating the efficacy or safety data of bimekizumab in the treatment of PsA. Data was pooled using the random-effects models. Egger tests were used to evaluate potential publication bias.
Results: A total of 4 RCTs, involving 892 PsA patients and 467 placebo controls, were included in this analysis. Bimekizumab significantly increased the rates of PASI75 and PASI100 compared with placebos [RR = 7.22, 95% CI (5.24, 9.94), p < 0.001; RR = 10.12, 95% CI (6.00, 17.09), < 0.001]. The rate of overall adverse events was slightly higher in the bimekizumab group [RR = 1.42, 95% CI (1.05, 1.93) = 0.023). However, there were fewer adverse severe drug reactions in the bimekizumab group compared to the placebo.
Conclusion: Bimekizumab had a significant clinical benefit in managing PsA and an acceptable safety profile.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/14740338.2024.2343017 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Feasibility study on fingerprinting organic and conventional mango fruits, chips, and juice using portable near-infrared spectroscopy.
Anal Methods
January 2025
Department of Food Science and Postharvest Technology, School of Applied Sciences and Technology, Cape Coast Technical University, Cape Coast, Ghana.
This research examined the distinction between organic and conventional mango fruits, chips, and juice using portable near-infrared (NIR) spectroscopy. A comprehensive analysis was conducted on a sample of 100 mangoes (comprising 50 organic and 50 conventional) utilising a portable NIR spectrometer that spans a wavelength range from 900 to 1700 nm. The mangoes were assessed in their entirety and their juice and chip forms.
View Article and Find Full Text PDFTIGIT and PVRIG are immune checkpoints co-expressed on activated T and NK cells, contributing to tumor immune evasion. Simultaneous blockade of these pathways may enhance therapeutic efficacy, positioning them as promising dual targets for cancer immunotherapy. This study aimed to develop a bispecific antibody (BsAb) to co-target TIGIT and PVRIG.
View Article and Find Full Text PDFThis meta-analysis focuses on the controversial efficacy and safety of microfragmented adipose tissue (MFAT) as compared with platelet-rich plasma (PRP) in the clinical treatment of knee osteoarthritis (KOA). We have attempted to provide an evidence-based medicine protocol for the conservative treatment of KOA. Researchers collected and compared randomized controlled trials (RCTs) that used microfragmented adipose tissue and platelet-rich plasma to treat knee osteoarthritis.
View Article and Find Full Text PDFImmunotherapy combined with chemotherapy without locoregional radiotherapy in metastatic nasopharyngeal carcinoma: two case reports and a literature review.
Front Immunol
January 2025
Department of Otolaryngology, Changhai Hospital, Naval Medical University, Shanghai, China.
Background: There is no consensus regarding the optimal regimen for metastatic nasopharyngeal carcinoma (dmNPC). Locoregional intensity modulated radiotherapy (LRRT) following palliative chemotherapy (PCT) has been shown to prolong the overall survival (OS) and improve the progression-free survival (PFS) of patients with dmNPC, compared with PCT alone. However, patients with a high tumor burden do not benefit from additional LRRT, which inevitably results in toxicity.
View Article and Find Full Text PDFEfficacy analysis of prophylactic hyperthermic intraperitoneal chemotherapy in patients with locally advanced gastric cancer: a retrospective study.
Front Oncol
January 2025
Second Department of Gastrointestinal Surgery, Maoming People's Hospital, Maoming, China.
Purpose: This study aims to evaluate the effectiveness and safety of prophylactic hyperthermic intraperitoneal chemotherapy (P-HIPEC) in patients with locally advanced gastric cancer (AGC) after laparoscopic radical gastrectomy. Additionally, it explores how the frequency and timing of P-HIPEC influence treatment outcomes.
Methods: A retrospective analysis was conducted on 227 patients with locally AGC who underwent laparoscopic surgery at Maoming People's Hospital from January 2016 to December 2022.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!